As part of CUNY’s ongoing Women in Science series, NYSCF CEO and Co-founder Susan L. Solomon was asked to speak at “Breaking Barriers to Success,” a panel discussion on how women make their way to the top of their fields. Solomon sat across other pioneering women in Science, Technology, Engineering and Math (STEM) outside of academia: Tracy Day, CEO and Co-founder of World Science Festival, and Reshma Saujani, CEO and Founder of Girls Who Code. The event series organized by CUNY’s Advanced Science Research Center aspires to help women develop professionally and build a community of women scientists.
The National Institute of Health (NIH) invited Susan Solomon to moderate a panel at September’s NIH Workshop on Reproducibility in Cell Culture Studies. The panel, within the “Emerging Challenges and Opportunities” session of the workshop focused on the difficulties of stem cells and engineered environments. Solomon explored the challenges of modeling diseases in a dish and approaches that NYSCF has taken to develop reproducible stem cell culture studies. Among conversations about guidelines for stem cell production and maintenance, genetic diversity represented by stem cells, and current biotechnology, the panel discussed how the NYSCF Global Stem Cell ArrayTM responds to the issues of reproducibility in the field by automating the production of stem cells to reduce human error and standardize the production of stem cells, increasing reproducibility of stem cell research. Dr. Scott Noggle, NYSCF Vice President of Stem Cell Research also participated on several other panels discussing various issues related to cell culture reproducibility.
Dr. Gary Gibson, Director of the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration at Weill Cornell Medical College, joined NYSCF as a visiting scientist while on sabbatical this year. Dr. Gibson’s work focuses on age-related neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The Wall Street Journal highlighted his recent research, which finds a connection between vitamin B1 deficits and Alzheimer’s disease.
This work is currently being tested in a clinical trial, administering a synthetic version of vitamin B1 to Alzheimer’s patients and analyzing the results. At NYSCF he will translate his work to stem cells to further elucidate the mechanisms of neurodegeneration.
NYSCF and the Korea Health Industry Development Institute (KHIDI) of the Republic of Korea held a ceremony to officially sign a five-year memorandum of understanding, or MOU, setting the stage for future collaborations in the areas of health care and medical science as they relate to stem cell research. This agreement will promote collaboration and development as well as exchange of information between KHIDI and NYSCF, and, more broadly, between the United States and Korea, accelerating stem cell research and cures on an international scale.
NYSCF - Robertson Neuroscience Investigator Dr. Gaby Maimon, The Rockefeller University, published his latest work studying visuomotor processing in fruit flies. The research, published in Nature Neuroscience, describes cellular and electrophysiological evidence that supports the theory that flies use active neural-circuit mechanisms to supress the perception of motion while flying. In addition, the scientists showed that these results mirror the visual supression of movement during rapid eye movement in primates.
Understanding neural image processing in animal models may lead to breakthoughs in our understanding of human visuomotor processing including pathologies related to visuomotor circuits.
NYSCF - Robertson Stem Cell Investigator Dr. Alex Meissner, Harvard University, published his latest work studying the development and interaction of binding factors in mouse stem cells. This research, published in Cell Stem Cell, studies how 'ground state' conditions affect pluripotency factor binding using two pathway inhibitors.
Understanding the specific steps and factors contributing to cell pluripotency is a necessary step in order to eventually develop successful future cell replacement treatments and therapies.